

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Diagnostics Assessment Programme

### Adjunctive colposcopy technologies for assessing suspected cervical abnormalities (update of DG4)

#### Provisional stakeholder list

<b>Manufacturer(s)</b> DYSIS Medical Ltd Zilico Ltd
<b>Manufacturer(s) of related technologies (not included in scope)</b> None
<b>Professional groups</b> British Association For Cytopathology British Society for Colposcopy and Cervical Pathology (BSCCP) Royal College Of Pathologists
<b>Patient/carer groups</b> Jo's Cervical Cancer Trust
<b>Research groups</b> Cancer Research UK
<b>Associated guideline groups</b>
<b>External Assessment Group</b> York Centre for Reviews and Dissemination
<b>Others</b> Cervical Screening Wales Department of Health Healthcare Improvement Scotland Medicines & Healthcare Products Regulatory Agency NHS England Public Health England Welsh Government

**Definitions:**Stakeholders

Individuals or organisations interested in a topic being evaluated by the Diagnostics Assessment Programme, and who register to become a stakeholder. For example, manufacturers of the technology, national organisations that represent healthcare professions who operate or use the results of the technology, national patient or carer organisations, NHS service providers and commissioners, statutory organisations and research organisations.

External Assessment Group (EAG)

An independent academic group commissioned by the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) that prepares a systematic review of the clinical and cost effectiveness of the technology(ies).